CA2469336C - Guanidinium transport reagents and conjugates - Google Patents

Guanidinium transport reagents and conjugates Download PDF

Info

Publication number
CA2469336C
CA2469336C CA2469336A CA2469336A CA2469336C CA 2469336 C CA2469336 C CA 2469336C CA 2469336 A CA2469336 A CA 2469336A CA 2469336 A CA2469336 A CA 2469336A CA 2469336 C CA2469336 C CA 2469336C
Authority
CA
Canada
Prior art keywords
biologically active
compound
active agent
group
transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2469336A
Other languages
English (en)
French (fr)
Other versions
CA2469336A1 (en
Inventor
Jonathan B. Rothbard
Paul A. Wender
Kanaka Pattabiraman
Erin T. Pelkey
Theodore C. Jessop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellGate Inc
Leland Stanford Junior University
Original Assignee
CellGate Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellGate Inc, Leland Stanford Junior University filed Critical CellGate Inc
Publication of CA2469336A1 publication Critical patent/CA2469336A1/en
Application granted granted Critical
Publication of CA2469336C publication Critical patent/CA2469336C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2469336A 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates Expired - Fee Related CA2469336C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33969601P 2001-12-11 2001-12-11
US60/339,696 2001-12-11
PCT/US2002/039698 WO2003049772A2 (en) 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates

Publications (2)

Publication Number Publication Date
CA2469336A1 CA2469336A1 (en) 2003-06-19
CA2469336C true CA2469336C (en) 2013-06-11

Family

ID=23330202

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2469336A Expired - Fee Related CA2469336C (en) 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates

Country Status (7)

Country Link
US (1) US7169814B2 (https=)
EP (1) EP1461084A2 (https=)
JP (1) JP2005538035A (https=)
AU (1) AU2002359679B2 (https=)
CA (1) CA2469336C (https=)
MX (1) MXPA04005611A (https=)
WO (1) WO2003049772A2 (https=)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP1301213B1 (en) 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
CA2523672C (en) * 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
GB0413613D0 (en) * 2004-06-17 2004-07-21 Univ London Small molecule carriers
WO2006010084A2 (en) * 2004-07-06 2006-01-26 Segev Laboratories Limited A system for delivering therapeutic agents into living cells and cell nuclei
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007038171A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
US7745392B2 (en) 2005-09-23 2010-06-29 Nitto Denko Corporation Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2007079394A2 (en) * 2005-12-30 2007-07-12 Revance Therapeutics, Inc. Arginine heteromers for topical administration
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
CA2655873C (en) 2006-07-14 2017-10-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
EP1905454A1 (en) * 2006-09-27 2008-04-02 Paolo Botti Formulations comprising cyclic compounds
EP2068936B1 (en) * 2006-09-27 2016-06-22 Paolo Botti Means and methods of enhancing delivery to biological systems
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
US9150612B2 (en) * 2007-02-23 2015-10-06 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
PT2144633E (pt) * 2007-04-23 2014-10-27 Deliversir Ltd Um sistema para a administração de agentes terapêuticos em células vivas e núcleos de células
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
EP3443976A1 (en) * 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
US7842762B2 (en) * 2007-08-08 2010-11-30 Ppg Industries Ohio, Inc. Electrodepositable coating composition containing a cyclic guanidine
WO2009099636A1 (en) * 2008-02-07 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Conjugation of small molecules to octaarginine transporters for overcoming multi-drug resistance
WO2010077732A2 (en) * 2008-12-09 2010-07-08 Aether Medical Llc Implantable analgesic
WO2010111533A2 (en) * 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9902957B2 (en) 2011-09-06 2018-02-27 The Board Of Trustees Of The Leland Stanford Junior University Amphipathic co-oligomers for the delivery of siRNA
WO2013162729A1 (en) 2012-04-24 2013-10-31 The Board Of Trustees Of The Leland Stanford Junior University Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
CN102863357B (zh) * 2012-09-20 2014-01-01 华中农业大学 具有植物生长调节活性的化合物及其制备方法
CN104918639B (zh) 2012-10-22 2018-01-26 萨拜格Rfa公司 用于将治疗剂递送到活细胞和细胞核中的系统
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9068089B2 (en) 2013-03-15 2015-06-30 Ppg Industries Ohio, Inc. Phenolic admix for electrodepositable coating composition containing a cyclic guanidine
US9688874B2 (en) 2013-10-25 2017-06-27 Ppg Industries Ohio, Inc. Method of making a bicyclic guanidine-cured acrylic coating
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
EP3613426A1 (en) 2014-05-21 2020-02-26 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016028700A1 (en) * 2014-08-18 2016-02-25 Washington State University Tunable ph-sensitive linker for controlled drug release
EP3185880B1 (en) 2014-08-27 2020-02-12 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US9854806B2 (en) 2015-05-19 2018-01-02 International Business Machines Corporation Antimicrobial guanidinium and thiouronium functionalized polymers
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
CN115252807A (zh) * 2016-07-27 2022-11-01 利兰斯坦福初级大学董事会 用于核酸递送的解体型细胞穿透性复合物
SMT202200366T1 (it) 2016-12-19 2022-11-18 Sarepta Therapeutics Inc Coniugati di oligomeri per salto di esone per distrofia muscolare
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
US11497759B2 (en) 2017-12-01 2022-11-15 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
EP3749365A4 (en) 2018-01-29 2022-01-12 Ohio State Innovation Foundation PEPTIDY INHIBITORS OF THE CALCINEURIN-NFAT INTERACTION
TW201945014A (zh) 2018-02-22 2019-12-01 美商安卓達治療股份有限公司 用於治療粒線體性神經胃腸腦病變之組合物及方法
CN119220109A (zh) 2018-03-30 2024-12-31 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
US10953039B2 (en) 2018-09-27 2021-03-23 International Business Machines Corporation Utilizing polymers and antibiotics to enhance antimicrobial activity and inhibit antibiotic resistance
MX2021002833A (es) 2018-09-27 2021-05-27 Biophysics Pharma Inc Sistema de suministro de farmaco transdermico.
US12246098B2 (en) 2018-09-27 2025-03-11 BioPhysics Pharma, Inc. Trans-epithelial membrane drug delivery system
CN118079011A (zh) * 2019-02-01 2024-05-28 利兰斯坦福初级大学董事会 用于将核酸递送至肺部的分解性细胞穿透复合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
JP2023532736A (ja) * 2020-07-02 2023-07-31 ユニバーシティー オブ ヒューストン システム 血液脳関門を通過する薬物送達のための化合物
WO2022115492A1 (en) 2020-11-24 2022-06-02 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2025250872A1 (en) * 2024-05-31 2025-12-04 Florida Atlantic University Board Of Trustees Antibody complementary determining region of heavy chain 3 mimics and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004074A (en) * 1968-06-18 1977-01-18 Colgate-Palmolive Company Highly substantive sunscreening agents
DE3310337A1 (de) * 1983-03-22 1984-09-27 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur durchfuehrung von hybridisierungsreaktionen
US5723496A (en) * 1991-03-05 1998-03-03 The Regents Of University Of California Method for prevention and treatment of harmful effects of intracellular acidosis
JP2651317B2 (ja) * 1992-06-18 1997-09-10 扶桑薬品工業株式会社 核酸の検出法
JP4320054B2 (ja) * 1996-08-13 2009-08-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ポリヌクレオチド送達のための組成物および方法
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
IL127773A0 (en) * 1998-12-28 1999-10-28 Yeda Res & Dev Saccharide conjugates and pharmaceutical compositions comprising them
US6593466B1 (en) * 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
CA2381425A1 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
MXPA03007358A (es) * 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.

Also Published As

Publication number Publication date
US20030185788A1 (en) 2003-10-02
US7169814B2 (en) 2007-01-30
AU2002359679B2 (en) 2009-01-08
EP1461084A2 (en) 2004-09-29
JP2005538035A (ja) 2005-12-15
WO2003049772A3 (en) 2003-11-20
US20040161405A9 (en) 2004-08-19
MXPA04005611A (es) 2005-04-19
AU2002359679A1 (en) 2003-06-23
WO2003049772A2 (en) 2003-06-19
CA2469336A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
CA2469336C (en) Guanidinium transport reagents and conjugates
ES2210761T3 (es) Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6593292B1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US6730293B1 (en) Compositions and methods for treating inflammatory diseases of the skin
US20020009491A1 (en) Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2006507322A (ja) 多重自己脱離放出スペーサーとして構築されたプロドラッグ
AU2001236920A1 (en) Compositions and methods for enhancing drug delivery across biological membranes and tissues
CA2438326A1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP1225917A2 (en) Manufacture of polyglutamate-therapeutic agent conjugates
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
Lu et al. Preparation, characterization, and in vitro efficacy of O-carboxymethyl chitosan conjugate of melphalan
ES2330079T3 (es) Direccionamiento de farmaco mediado par la integrina.
EP1304122A2 (en) Composition and method for enhancing transport across biological membrane
HK1152869A (en) Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
MXPA99010704A (en) Composition and method for enhancing transport across biological membranes
AU2002303102A1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
HK1155363A (en) Novel dual targeting antitumoural conjugates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151211